title: Desferrioxamine shows different potentials for enhancing 5-aminolaevulinic acid-based photodynamic therapy in several cutaneous cell lines.
abstract: Protoporphyrin IX (PpIX) is the photosensitizer in 5-aminolaevulinic acid (ALA)-based photodynamic therapy (PDT). Its further bioconversion to heme requires iron and can be suppressed by iron chelators such as desferrioxamine (DFO). To investigate the effectiveness of DFO in enhancing PpIX-based PDT in skin tissue, we selected fibroblasts, HaCat cells and Hep-2 cells as targets co-cultured with ALA, that have different biological characteristics for PpIX conversion. Evaluated interventions included: (1) blank control (no ALA, no DFO); (2) DFO alone; (3) ALA alone; and (4) DFO in combination with ALA. Before photodynamic irradiation, cellular PpIX level and fluorescence were measured. After irradiation, cell death ratio was calculated and morphological changes in the cells were observed. The results showed that the content and photodynamic effects of cellular PpIX presented in the order Hep-2 cells > HaCat cells > fibroblasts, either co-cultured with ALA alone or with ALA plus DFO. DFO was found to have increasing effects on both PpIX level and cell death ratio in the same order. It was found that DFO had different potentials for augmenting ALA-PDT in these cutaneous cell lines. The cells proliferating more rapidly might be more susceptible to enhancement of DFO.
authors.affiliation: Department of Dermatology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
authors.forename: Jiabin
authors.initials: J
authors.lastname: Yang
authors.forename: Yumin
authors.initials: Y
authors.lastname: Xia
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Liu
authors.forename: Shan
authors.initials: S
authors.lastname: Jiang
authors.forename: Layuan
authors.initials: L
authors.lastname: Xiong
mesh_terms: D000622:Aminolevulinic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D016923:Cell Death / Q000187:drug effects; D002460:Cell Line; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D004357:Drug Synergism; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011524:Protoporphyrins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D012871:Skin Diseases / Q000188:drug therapy
chemical_list: D007502:Iron Chelating Agents; D017319:Photosensitizing Agents; D011524:Protoporphyrins; D000622:Aminolevulinic Acid; C028025:protoporphyrin IX; D003676:Deferoxamine
references.citation: Photodermatol Photoimmunol Photomed. 2008 Oct;24(5):237-43
references.pmid: 18811864
references.citation: Lasers Surg Med. 2004;34(1):62-72
references.pmid: 14755426
references.citation: Folia Histochem Cytobiol. 2005;43(3):129-32
references.pmid: 16201311
references.citation: J Environ Pathol Toxicol Oncol. 2007;26(2):75-82
references.pmid: 17725533
references.citation: Photochem Photobiol Sci. 2004 Mar;3(3):263-7
references.pmid: 14993942
references.citation: Br J Dermatol. 2008 Dec;159(6):1245-66
references.pmid: 18945319
references.citation: Lasers Surg Med. 2008 Feb;40(2):153-8
references.pmid: 18306163
references.citation: Eur J Pharm Biopharm. 2006 Jul;63(3):295-309
references.pmid: 16682177
references.citation: J Biomed Opt. 2008 Mar-Apr;13(2):024014
references.pmid: 18465977
references.citation: Chin Med J (Engl). 2004 Jun;117(6):922-6
references.pmid: 15198900
references.citation: J Cardiovasc Pharmacol. 2005 Jun;45(6):539-44
references.pmid: 15897780
references.citation: Int J Biochem Cell Biol. 2005 Feb;37(2):272-6
references.pmid: 15474973
references.citation: Photochem Photobiol Sci. 2007 Dec;6(12):1268-74
references.pmid: 18046481
references.citation: Photochem Photobiol. 2007 May-Jun;83(3):766-73
references.pmid: 17576385
references.citation: Photochem Photobiol Sci. 2008 Mar;7(3):283-9
references.pmid: 18389144
references.citation: Exp Dermatol. 2007 Aug;16(8):651-60
references.pmid: 17620092
references.citation: World J Gastroenterol. 2008 Apr 14;14(14):2174-8
references.pmid: 18407590
references.citation: J Invest Dermatol. 2006 Dec;126(12):2679-86
references.pmid: 16841035
references.citation: Exp Dermatol. 2004 Jul;13(7):445-51
references.pmid: 15217365
references.citation: J Pharm Pharmacol. 1999 Feb;51(2):131-4
references.pmid: 10217310
references.citation: Lasers Surg Med. 2005 Jun;36(5):398-408
references.pmid: 15856508
references.citation: Exp Oncol. 2005 Mar;27(1):81-3
references.pmid: 15812364
references.citation: Photochem Photobiol. 2002 Apr;75(4):418-23
references.pmid: 12003133
references.citation: Pharm Res. 2006 Feb;23(2):360-6
references.pmid: 16341572
references.citation: Br J Dermatol. 2008 Jul;159(1):61-7
references.pmid: 18489589
references.citation: Cancer. 2001 Dec 15;92(12):3093-110
references.pmid: 11753989
references.citation: J Environ Pathol Toxicol Oncol. 2006;25(1-2):403-9
references.pmid: 16566731
references.citation: J Gastroenterol. 2007 Jun;42(6):475-84
references.pmid: 17671763
references.citation: J Environ Pathol Toxicol Oncol. 2007;26(2):89-103
references.pmid: 17725535
references.citation: Biochem Pharmacol. 2007 Nov 1;74(9):1401-12
references.pmid: 17714696
references.citation: J Natl Compr Canc Netw. 2007 May;5(5):531-40
references.pmid: 17509255
references.citation: Dermatology. 2009;218(3):193-202
references.pmid: 19077380
references.citation: J Photochem Photobiol B. 2004 Jan 23;73(1-2):67-78
references.pmid: 14732253